Welcome to our dedicated page for Amarin SEC filings (Ticker: AMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amarin Corporation plc (NASDAQ: AMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Amarin is a global pharmaceutical company focused on cardiovascular disease and the commercialization of its icosapent ethyl product, VASCEPA/VAZKEPA. Its filings offer detailed insight into how the business is structured, how key agreements are arranged and how financial performance is reported.
Investors can use this page to review current reports on Form 8-K, where Amarin discloses material events such as quarterly financial results, global restructuring actions and major licensing arrangements. For example, a Form 8-K describes the exclusive long-term license and supply agreement with Recordati to develop and commercialize VAZKEPA in 59 European-focused countries, as well as the associated global restructuring plan aimed at reducing operating costs. Other 8-K filings address financial results for specific quarters and executive appointments.
In addition to 8-Ks, Amarin’s periodic reports on Form 10-K and Form 10-Q (referenced in its press releases) contain more comprehensive discussions of revenue from VASCEPA/VAZKEPA, licensing and royalty income, operating expenses, restructuring charges and risk factors related to cardiovascular therapeutics and global commercialization. These documents are central for understanding the company’s balance sheet, cash position, cost structure and exposure to clinical, regulatory and market risks.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as the nature of material agreements, the scale and timing of restructuring plans, and the implications of licensing deals for future revenue streams. Users can quickly identify items related to Amarin’s cardiovascular franchise, including references to VASCEPA/VAZKEPA, global partners and restructuring initiatives, while retaining the ability to drill down into the full SEC documents for complete context.
Amarin Corporation plc President and CEO Aaron Berg reported several equity compensation events and related share movements. On February 1, 2026, he received 26,793 restricted stock units (RSUs) and a stock option for 120,566 American Depositary Shares (ADSs) under Amarin’s 2020 Stock Incentive Plan.
Each RSU represents a contingent right to receive twenty ordinary shares or cash. On January 31, 2026, previously granted RSUs vested, converting into 2,246 ADSs and 1,933 ADSs. The company withheld 1,235 ADSs and 1,063 ADSs at $15.42 per ADS to cover tax liabilities, which is explicitly described as not being market sales.
The filing notes a prior ADS ratio change effective April 11, 2025, where one ADS now represents twenty ordinary shares, and all reported amounts reflect this adjusted ratio.
Amarin Corporation’s EVP and Chief Legal Officer, Jonathan Provoost, reported new equity awards dated February 1, 2026. He received 8,013 Restricted Stock Units (RSUs)stock option for 36,060 American Depositary Shares (ADSs) under the 2020 Stock Incentive Plan.
The 8,013 RSUs vest in three equal installments on January 31, 2027, January 31, 2028 and January 31, 2029. The 36,060 ADS option vests over three years, with 33% vesting on the first anniversary of the grant date and the remainder vesting quarterly over the following eight calendar quarters. The filing notes that, effective April 11, 2025, one ADS represents twenty ordinary shares and that the reported award amounts already reflect this ratio change.
Amarin Corporation’s SVP and CFO Peter L. Fishman reported equity compensation and related share activity. On February 1, 2026, he received 6,167 restricted stock units (RSUs) and a stock option for 27,750 American Depositary Shares (ADSs) with a $14.99 exercise price, all under the company’s stock plan.
These RSUs vest in three equal installments on January 31 of 2027, 2028, and 2029. On January 31, 2026, previously granted RSUs vested, resulting in the issuance of 563 and 1,833 ADSs, with 310 and 1,008 ADSs withheld at $15.42 per share to cover tax obligations rather than sold in the market.
Amarin Corporation executive Steven B. Ketchum reported multiple equity compensation events and related share movements. On January 31, 2026, previously granted RSUs vested, converting into 2,246 and 1,933 American Depositary Shares (ADS). The company withheld 1,235 and 1,062 ADS at
On February 1, 2026, Ketchum received new awards under Amarin’s 2020 Stock Incentive Plan: 8,013 Restricted Stock Units and a stock option for 36,060 ADS with an exercise price of
Amarin Corporation’s EVP and Chief Operating Officer David Paul Keenan reported routine equity compensation activity and tax withholding around RSU vesting. On January 31, 2026, previously granted restricted stock units converted into American Depositary Shares (ADSs), with 2,246 ADSs and 1,933 ADSs delivered and portions of each vest used to cover taxes through share withholding at $15.42 per ADS.
On February 1, 2026, Keenan received a new grant of 8,013 restricted stock units and 30,060 stock options under Amarin’s 2020 Stock Incentive Plan, with the RSUs and options scheduled to vest over three years. Each RSU represents a contingent right to receive twenty ordinary shares or cash, reflecting a prior change so that 1 ADS equals 20 ordinary shares.
Amarin Corporation plc filed a current report to note that it has released a press release with its preliminary unaudited 2025 financial highlights. The release also summarizes key operational accomplishments for 2025 and outlines the company’s priorities for 2026. This information is being furnished as an exhibit rather than filed, which limits how it is incorporated into other regulatory documents.
Amarin Corporation’s EVP and Chief Operating Officer, Keenan David Paul, reported routine equity compensation activity. On January 2, 2026, 3,688 Restricted Stock Units vested into the right to receive American Depositary Shares at an exercise price of $0.00. These were reflected as 3,688 American Depositary Shares acquired through an option exercise transaction.
To cover tax obligations related to the vesting, the company withheld 1,926 American Depositary Shares at a price of $13.96 per share, which the filing notes was not a market sale. After these transactions, the executive directly owned 9,712 American Depositary Shares and 3,688 RSUs. The filing also reminds investors that one ADS currently represents twenty ordinary shares following an earlier ADS ratio change.
Amarin Corporation EVP and Chief Scientific Officer Steven B. Ketchum reported equity compensation activity involving American Depositary Shares (ADSs) and restricted stock units (RSUs). On January 2, 2026, 3,688 RSUs were credited at an exercise price of $0, each representing a contingent right to receive twenty ordinary shares or cash. The same day, 3,688 ADS were acquired in a transaction coded "M," leaving 41,038 ADS directly held.
A separate transaction coded "F" shows 2,041 ADS withheld at $13.96 per ADS to cover tax liabilities tied to the vesting, reducing directly held ADS to 38,997. These RSUs were part of a 7,376‑unit grant awarded on January 10, 2025 under Amarin’s 2020 Stock Incentive Plan, scheduled to vest 50% on January 2, 2026 and the remainder on July 1, 2026. The company had previously changed its ADS ratio so that one ADS represents twenty ordinary shares, and all reported amounts reflect this ratio.
Amarin Corporation plc (AMRN) — Initial insider ownership filed. The company’s EVP and Chief Operating Officer filed a Form 3 as of 10/17/2025, reporting 7,950 American Depositary Shares (ADS) held directly.
Reported derivative holdings include Restricted Stock Units covering 6,740, 5,800, and 7,376 ADS, and stock options for 33,193 ADS at $12.4 expiring 01/10/2035, 20,900 ADS at $24.2 expiring 02/01/2034, 13,480 ADS at $36 expiring 02/21/2033, and 5,000 ADS at $29 expiring 06/01/2032. The filing notes an April 11, 2025 ADS ratio change where 1 ADS represents 20 Ordinary Shares, with equity awards adjusted accordingly. RSU and option grants vest on schedules described, generally in annual or quarterly tranches over 18 months to four years.
Amarin Corporation plc reported Q3 2025 results. Total revenue was $49.7 million (up from $42.3 million a year ago), driven by product revenue of $48.6 million and licensing and royalty revenue of $1.1 million. The company posted a net loss of $7.7 million, a significant improvement from a $25.1 million loss in Q3 2024, as operating expenses declined, particularly selling, general and administrative costs.
Gross margin was $22.2 million on cost of goods sold of $27.5 million. Amarin recorded $9.4 million of restructuring expense in the quarter and $32.2 million year‑to‑date tied to its June 24, 2025 global restructuring plan associated with its Recordati agreement, with expected total charges of $30.0–$37.0 million, substantially all cash.
Liquidity remains solid with $122.8 million in cash and cash equivalents and $163.8 million in short‑term investments as of September 30, 2025, and no outstanding debt. Year‑to‑date, revenue was $164.4 million and net loss $37.6 million. U.S. product revenue led the quarter at $40.9 million, with Europe at $4.1 million and Rest of World at $3.6 million.
FAQ
What is the current stock price of Amarin (AMRN)?
What is the market cap of Amarin (AMRN)?
